SAN FRANCISCO, Sept. 15, 2016 /PRNewswire/ -- Kindred
Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company
focused on saving and improving the lives of pets, today announced
that Stephen Sundlof, DVM, PhD,
Chief Scientific Officer and Executive Vice President, Regulatory
Affairs and Quality, will be serving on a panel at the BIO Animal
Biotech Summit in Bethesda,
Maryland on Thursday, September 22,
2016 at 3.30pm EDT. The panel
discussion, titled "Barriers to Innovation: Regulation and
Politics," will discuss the role of regulation in facilitating or
impeding technological innovation. The conference is being held in
the Grand Ballroom of the Bethesda Marriott.
About Kindred Biosciences, Inc.
Kindred Biosciences is a development-stage biopharmaceutical
company focused on saving and improving the lives of pets.
Its mission is to bring to pets the same kinds of safe and
effective medicines that human family members enjoy. The
Company's strategy is to identify compounds and targets that have
already demonstrated safety and efficacy in humans and to develop
therapeutics based on these validated compounds and targets for
dogs, cats and horses. The Company has a deep pipeline of
novel drugs and biologics in development across many therapeutic
classes.
For more information or to download the corporate presentation,
visit www.KindredBio.com/LearnMore. Stay connected with KindredBio
on Facebook at www.Facebook.com/KindredBio.
Contact
Russell Radefeld
KindredBio
Russell.radefeld@kindredbio.com
(650) 701-7904
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/kindred-biosciences-to-participate-in-a-bio-animal-biotech-summit-panel-300329025.html
SOURCE Kindred Biosciences, Inc.